Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Embolic protection tech firm nets $6.7m in series B

This article was originally published in Clinica

Executive Summary

Embrella Cardiovascular has secured $6.7m in a series B financing round led by BioStar Ventures and the MedFocus Fund. The new capital, which also included investments made by Edwards Lifesciences and Hatteras Venture Partners, will enable Wayne, Pennsylvania-based Embrella to complete European clinical trials of its Embolic Deflector device and submit the data for CE mark approval. The product will be used in procedures such as transcatheter aortic valve implantation, which is carried out on high-risk patients with severe aortic stenosis. The Embrella Embolic Deflector is designed to prevent emboli that are dislodged during the procedure from entering the brain by deflecting them away from the carotid arteries.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel